Concepts (265)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Onchocerciasis | 25 | 2019 | 64 | 13.50 | Why? |
| Epilepsy | 22 | 2021 | 1401 | 6.20 | Why? |
| Ivermectin | 12 | 2019 | 973 | 3.06 | Why? |
| Onchocerca volvulus | 8 | 2019 | 23 | 2.59 | Why? |
| Antiparasitic Agents | 6 | 2019 | 267 | 2.14 | Why? |
| Nodding Syndrome | 5 | 2019 | 8 | 2.10 | Why? |
| Endemic Diseases | 7 | 2019 | 480 | 1.71 | Why? |
| Mass Drug Administration | 3 | 2019 | 143 | 1.64 | Why? |
| Guideline Adherence | 5 | 2021 | 2309 | 1.40 | Why? |
| Democratic Republic of the Congo | 8 | 2021 | 500 | 1.37 | Why? |
| HIV Infections | 23 | 2021 | 11620 | 1.00 | Why? |
| Disease Eradication | 2 | 2018 | 581 | 0.89 | Why? |
| Hemorrhagic Fever, Ebola | 3 | 2017 | 1475 | 0.86 | Why? |
| Anticonvulsants | 3 | 2020 | 634 | 0.83 | Why? |
| Tauopathies | 1 | 2019 | 14 | 0.83 | Why? |
| Anti-Retroviral Agents | 7 | 2018 | 1099 | 0.83 | Why? |
| Ebolavirus | 2 | 2017 | 834 | 0.83 | Why? |
| Antinematodal Agents | 1 | 2019 | 41 | 0.80 | Why? |
| Malaria | 2 | 2019 | 1097 | 0.78 | Why? |
| Social Stigma | 2 | 2019 | 1049 | 0.75 | Why? |
| Onchocerciasis, Ocular | 1 | 2018 | 7 | 0.74 | Why? |
| Tanzania | 5 | 2019 | 294 | 0.72 | Why? |
| Filoviridae | 1 | 2018 | 70 | 0.71 | Why? |
| Focus Groups | 2 | 2019 | 811 | 0.70 | Why? |
| Isoindoles | 1 | 2018 | 195 | 0.69 | Why? |
| Smallpox | 1 | 2018 | 96 | 0.68 | Why? |
| Prevalence | 20 | 2021 | 25773 | 0.65 | Why? |
| South Sudan | 4 | 2018 | 107 | 0.62 | Why? |
| Tropical Medicine | 1 | 2018 | 237 | 0.59 | Why? |
| Intimate Partner Violence | 1 | 2021 | 363 | 0.58 | Why? |
| Medicine, Traditional | 1 | 2017 | 189 | 0.58 | Why? |
| Uganda | 11 | 2021 | 1057 | 0.58 | Why? |
| Immune Reconstitution Inflammatory Syndrome | 3 | 2018 | 66 | 0.53 | Why? |
| Guidelines as Topic | 3 | 2021 | 2844 | 0.51 | Why? |
| Prejudice | 2 | 2021 | 245 | 0.50 | Why? |
| Belgium | 5 | 2020 | 2064 | 0.50 | Why? |
| Africa South of the Sahara | 6 | 2020 | 1335 | 0.48 | Why? |
| Surveys and Questionnaires | 17 | 2021 | 43792 | 0.47 | Why? |
| Therapies, Investigational | 1 | 2014 | 235 | 0.46 | Why? |
| Encephalitis | 1 | 2019 | 797 | 0.46 | Why? |
| Young Adult | 29 | 2021 | 93724 | 0.46 | Why? |
| Tuberculosis | 5 | 2018 | 2895 | 0.45 | Why? |
| Adolescent | 30 | 2021 | 86841 | 0.43 | Why? |
| Molecular Typing | 1 | 2012 | 280 | 0.42 | Why? |
| Rural Population | 8 | 2019 | 2408 | 0.42 | Why? |
| Medication Adherence | 2 | 2017 | 1270 | 0.41 | Why? |
| Cross-Sectional Studies | 22 | 2021 | 53120 | 0.41 | Why? |
| Seizures | 4 | 2021 | 1163 | 0.41 | Why? |
| Adult | 46 | 2021 | 244371 | 0.40 | Why? |
| Community Health Services | 1 | 2019 | 1000 | 0.39 | Why? |
| Simuliidae | 2 | 2019 | 8 | 0.39 | Why? |
| Wuchereria bancrofti | 2 | 2019 | 13 | 0.39 | Why? |
| Antibodies, Helminth | 2 | 2019 | 48 | 0.39 | Why? |
| Onygenales | 2 | 2018 | 11 | 0.37 | Why? |
| Elephantiasis, Filarial | 2 | 2019 | 47 | 0.36 | Why? |
| Cameroon | 5 | 2021 | 464 | 0.35 | Why? |
| Rivers | 3 | 2018 | 304 | 0.35 | Why? |
| Internationality | 1 | 2021 | 3297 | 0.35 | Why? |
| Transients and Migrants | 2 | 2017 | 1468 | 0.34 | Why? |
| Humans | 77 | 2021 | 930598 | 0.34 | Why? |
| Child | 21 | 2020 | 70012 | 0.33 | Why? |
| Leishmaniasis, Visceral | 2 | 2017 | 85 | 0.32 | Why? |
| Female | 46 | 2021 | 380317 | 0.31 | Why? |
| Male | 46 | 2021 | 367725 | 0.31 | Why? |
| Disease Outbreaks | 7 | 2021 | 27595 | 0.30 | Why? |
| AIDS-Related Opportunistic Infections | 2 | 2018 | 260 | 0.30 | Why? |
| Geography, Medical | 2 | 2018 | 537 | 0.30 | Why? |
| Health Behavior | 2 | 2021 | 4449 | 0.30 | Why? |
| Health Services Accessibility | 2 | 2020 | 10697 | 0.30 | Why? |
| Child, Preschool | 12 | 2019 | 36283 | 0.30 | Why? |
| Violence | 2 | 2021 | 534 | 0.29 | Why? |
| Sexual Behavior | 3 | 2019 | 1322 | 0.27 | Why? |
| Mycobacterium tuberculosis | 2 | 2017 | 1164 | 0.26 | Why? |
| Anti-HIV Agents | 4 | 2020 | 2209 | 0.24 | Why? |
| Brain | 1 | 2019 | 5133 | 0.23 | Why? |
| Public Health | 4 | 2021 | 16359 | 0.23 | Why? |
| Benin | 1 | 2021 | 115 | 0.22 | Why? |
| Middle Aged | 25 | 2021 | 270681 | 0.22 | Why? |
| Ethiopia | 4 | 2017 | 1222 | 0.22 | Why? |
| Mycoses | 2 | 2018 | 589 | 0.22 | Why? |
| Europe, Eastern | 1 | 2020 | 88 | 0.22 | Why? |
| Africa | 3 | 2019 | 2986 | 0.22 | Why? |
| Mozambique | 1 | 2021 | 205 | 0.21 | Why? |
| Neurofibrillary Tangles | 1 | 2019 | 18 | 0.21 | Why? |
| Anxiety | 3 | 2021 | 17311 | 0.21 | Why? |
| Logistic Models | 3 | 2021 | 9089 | 0.21 | Why? |
| Phenobarbital | 1 | 2019 | 22 | 0.21 | Why? |
| Depression | 3 | 2021 | 14116 | 0.20 | Why? |
| Tissue Inhibitor of Metalloproteinases | 1 | 2018 | 7 | 0.19 | Why? |
| Mycotoxins | 1 | 2018 | 19 | 0.19 | Why? |
| Infant | 6 | 2019 | 30274 | 0.19 | Why? |
| Mansonella | 1 | 2018 | 2 | 0.19 | Why? |
| Ecuador | 1 | 2021 | 514 | 0.19 | Why? |
| Microbiological Techniques | 2 | 2018 | 232 | 0.19 | Why? |
| Anopheles | 1 | 2019 | 89 | 0.19 | Why? |
| Schistosomiasis mansoni | 1 | 2018 | 35 | 0.18 | Why? |
| Sexual Partners | 2 | 2021 | 612 | 0.18 | Why? |
| CD4 Lymphocyte Count | 6 | 2018 | 1517 | 0.18 | Why? |
| Animals | 13 | 2019 | 78931 | 0.18 | Why? |
| Age Distribution | 2 | 2018 | 3567 | 0.18 | Why? |
| Incidence | 6 | 2019 | 25622 | 0.18 | Why? |
| Risk Factors | 10 | 2021 | 71621 | 0.18 | Why? |
| Soil Microbiology | 1 | 2018 | 63 | 0.17 | Why? |
| Matrix Metalloproteinases | 1 | 2018 | 131 | 0.17 | Why? |
| Patient Health Questionnaire | 1 | 2020 | 625 | 0.17 | Why? |
| Waist Circumference | 1 | 2018 | 199 | 0.17 | Why? |
| Ascomycota | 1 | 2018 | 71 | 0.17 | Why? |
| Aqueous Humor | 1 | 2018 | 82 | 0.17 | Why? |
| Food Contamination | 1 | 2018 | 142 | 0.17 | Why? |
| Cost of Illness | 2 | 2018 | 1903 | 0.17 | Why? |
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 502 | 0.17 | Why? |
| Attitude to Health | 1 | 2010 | 2002 | 0.16 | Why? |
| Infant, Newborn | 4 | 2019 | 23105 | 0.16 | Why? |
| Coinfection | 6 | 2018 | 6820 | 0.16 | Why? |
| AIDS Serodiagnosis | 1 | 2017 | 64 | 0.16 | Why? |
| Psychology | 1 | 2020 | 447 | 0.16 | Why? |
| Neurologists | 1 | 2019 | 283 | 0.16 | Why? |
| Case-Control Studies | 4 | 2019 | 17671 | 0.16 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 8811 | 0.15 | Why? |
| Zambia | 1 | 2017 | 401 | 0.15 | Why? |
| Insect Vectors | 1 | 2018 | 227 | 0.15 | Why? |
| Benzamides | 1 | 2018 | 421 | 0.15 | Why? |
| Health Risk Behaviors | 1 | 2017 | 172 | 0.15 | Why? |
| Age of Onset | 1 | 2017 | 557 | 0.15 | Why? |
| Activities of Daily Living | 2 | 2021 | 1530 | 0.14 | Why? |
| Socioeconomic Factors | 4 | 2018 | 8495 | 0.14 | Why? |
| Infectious Disease Medicine | 1 | 2018 | 311 | 0.14 | Why? |
| Urban Population | 3 | 2017 | 2000 | 0.14 | Why? |
| Brazil | 3 | 2021 | 12582 | 0.14 | Why? |
| Vietnam | 4 | 2021 | 1665 | 0.14 | Why? |
| Culture | 1 | 2018 | 370 | 0.14 | Why? |
| Cataract | 1 | 2018 | 186 | 0.14 | Why? |
| Neutrophil Activation | 1 | 2018 | 510 | 0.14 | Why? |
| Prednisone | 1 | 2018 | 652 | 0.14 | Why? |
| Tuberculosis, Meningeal | 1 | 2015 | 100 | 0.13 | Why? |
| Hygiene | 1 | 2021 | 987 | 0.13 | Why? |
| Hand Disinfection | 2 | 2021 | 1671 | 0.13 | Why? |
| Cerebrospinal Fluid | 1 | 2015 | 234 | 0.13 | Why? |
| Cognition Disorders | 1 | 2018 | 574 | 0.12 | Why? |
| Microscopy | 2 | 2017 | 414 | 0.12 | Why? |
| Communicable Disease Control | 6 | 2021 | 29620 | 0.12 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.12 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.12 | Why? |
| Pandemics | 14 | 2021 | 389249 | 0.12 | Why? |
| Aged | 14 | 2021 | 215776 | 0.12 | Why? |
| Advisory Committees | 1 | 2019 | 1418 | 0.11 | Why? |
| Nigeria | 1 | 2019 | 2292 | 0.11 | Why? |
| Tuberculosis, Pulmonary | 2 | 2018 | 1171 | 0.11 | Why? |
| Sentinel Surveillance | 1 | 2018 | 1093 | 0.11 | Why? |
| South Africa | 5 | 2018 | 3326 | 0.11 | Why? |
| DNA, Bacterial | 1 | 2015 | 835 | 0.11 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2017 | 952 | 0.11 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.11 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.11 | Why? |
| Patient Compliance | 1 | 2020 | 1468 | 0.11 | Why? |
| Lipopolysaccharides | 1 | 2015 | 848 | 0.11 | Why? |
| Demography | 1 | 2017 | 1660 | 0.10 | Why? |
| Disease Management | 2 | 2018 | 6841 | 0.10 | Why? |
| Molecular Diagnostic Techniques | 2 | 2017 | 4239 | 0.10 | Why? |
| Delivery of Health Care | 3 | 2021 | 15909 | 0.10 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.10 | Why? |
| Masks | 3 | 2021 | 8528 | 0.10 | Why? |
| Multivariate Analysis | 2 | 2018 | 5440 | 0.10 | Why? |
| Mali | 2 | 2019 | 181 | 0.09 | Why? |
| Sputum | 2 | 2017 | 1720 | 0.09 | Why? |
| Seroepidemiologic Studies | 2 | 2021 | 10017 | 0.09 | Why? |
| Air Microbiology | 1 | 2018 | 1322 | 0.09 | Why? |
| Interviews as Topic | 1 | 2017 | 1952 | 0.08 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2016 | 1138 | 0.08 | Why? |
| Ambulatory Care Facilities | 1 | 2019 | 2063 | 0.08 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.08 | Why? |
| Family Characteristics | 1 | 2017 | 2551 | 0.08 | Why? |
| Molecular Epidemiology | 1 | 2012 | 1638 | 0.08 | Why? |
| Remote Consultation | 1 | 2021 | 2396 | 0.08 | Why? |
| Information Dissemination | 1 | 2021 | 2986 | 0.07 | Why? |
| Body Mass Index | 1 | 2018 | 4306 | 0.07 | Why? |
| Follow-Up Studies | 2 | 2021 | 17020 | 0.07 | Why? |
| Public Health Surveillance | 1 | 2018 | 3129 | 0.07 | Why? |
| World Health Organization | 1 | 2018 | 4213 | 0.07 | Why? |
| Immunoglobulin G | 2 | 2019 | 21571 | 0.07 | Why? |
| Developing Countries | 1 | 2020 | 4283 | 0.07 | Why? |
| Caregivers | 1 | 2019 | 3112 | 0.07 | Why? |
| Quarantine | 2 | 2021 | 18418 | 0.06 | Why? |
| Emergencies | 1 | 2018 | 4095 | 0.06 | Why? |
| HIV-1 | 1 | 2018 | 3365 | 0.06 | Why? |
| Internet | 1 | 2021 | 6204 | 0.06 | Why? |
| Geography | 2 | 2018 | 1801 | 0.06 | Why? |
| Education, Medical | 1 | 2018 | 2461 | 0.05 | Why? |
| Prospective Studies | 4 | 2018 | 43301 | 0.05 | Why? |
| Genotype | 1 | 2012 | 4697 | 0.05 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.05 | Why? |
| Africa, Eastern | 1 | 2019 | 90 | 0.05 | Why? |
| Anti-Inflammatory Agents | 1 | 2018 | 6153 | 0.05 | Why? |
| Edible Grain | 1 | 2018 | 26 | 0.05 | Why? |
| Immunoassay | 1 | 2015 | 4485 | 0.05 | Why? |
| Microfilariae | 1 | 2018 | 5 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.05 | Why? |
| DNA, Ribosomal Spacer | 1 | 2018 | 49 | 0.05 | Why? |
| Schistosoma mansoni | 1 | 2018 | 27 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.05 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.05 | Why? |
| Breeding | 1 | 2018 | 60 | 0.05 | Why? |
| Parasitemia | 1 | 2018 | 88 | 0.04 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 11367 | 0.04 | Why? |
| Lost to Follow-Up | 1 | 2017 | 79 | 0.04 | Why? |
| Ascites | 1 | 2017 | 65 | 0.04 | Why? |
| Haiti | 1 | 2017 | 175 | 0.04 | Why? |
| Health Personnel | 4 | 2021 | 29646 | 0.04 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.04 | Why? |
| Directive Counseling | 1 | 2017 | 77 | 0.04 | Why? |
| Zimbabwe | 1 | 2017 | 198 | 0.04 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.04 | Why? |
| Immunologic Tests | 1 | 2019 | 445 | 0.04 | Why? |
| Mammals | 1 | 2018 | 315 | 0.04 | Why? |
| Jaundice | 1 | 2017 | 114 | 0.04 | Why? |
| Cohort Studies | 5 | 2018 | 36005 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| Cytokines | 1 | 2018 | 15010 | 0.04 | Why? |
| Random Allocation | 1 | 2018 | 773 | 0.04 | Why? |
| Kenya | 1 | 2018 | 887 | 0.04 | Why? |
| Tobacco Use | 1 | 2018 | 340 | 0.04 | Why? |
| Survival Analysis | 2 | 2018 | 7592 | 0.03 | Why? |
| Neglected Diseases | 1 | 2019 | 381 | 0.03 | Why? |
| Adolescent Behavior | 1 | 2019 | 400 | 0.03 | Why? |
| Capacity Building | 1 | 2018 | 683 | 0.03 | Why? |
| Antitubercular Agents | 1 | 2018 | 775 | 0.03 | Why? |
| Health Services Research | 1 | 2018 | 756 | 0.03 | Why? |
| Overweight | 1 | 2018 | 916 | 0.03 | Why? |
| Hemoglobins | 1 | 2017 | 958 | 0.03 | Why? |
| Lymph Nodes | 1 | 2018 | 1060 | 0.03 | Why? |
| Policy | 1 | 2018 | 1372 | 0.03 | Why? |
| Immunohistochemistry | 1 | 2018 | 2275 | 0.03 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.02 | Why? |
| Flow Cytometry | 1 | 2018 | 2393 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Homosexuality, Male | 1 | 2016 | 1158 | 0.02 | Why? |
| Recurrence | 1 | 2017 | 3675 | 0.02 | Why? |
| Disabled Persons | 1 | 2018 | 1152 | 0.02 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2018 | 5814 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.02 | Why? |
| Alcohol Drinking | 1 | 2018 | 1663 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2018 | 3788 | 0.02 | Why? |
| Skin | 1 | 2018 | 2096 | 0.02 | Why? |
| Fear | 1 | 2021 | 3607 | 0.02 | Why? |
| Retrospective Studies | 4 | 2018 | 105322 | 0.02 | Why? |
| Research | 1 | 2018 | 2115 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2017 | 22971 | 0.02 | Why? |
| Treatment Outcome | 3 | 2018 | 51732 | 0.02 | Why? |
| Hemorrhage | 1 | 2017 | 3013 | 0.02 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.02 | Why? |
| Autopsy | 1 | 2015 | 3495 | 0.02 | Why? |
| Diagnostic Tests, Routine | 1 | 2015 | 2643 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 7868 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Travel | 1 | 2020 | 7220 | 0.01 | Why? |
| Point-of-Care Systems | 1 | 2015 | 2955 | 0.01 | Why? |
| Immunologic Factors | 1 | 2018 | 4206 | 0.01 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.01 | Why? |
| Europe | 1 | 2016 | 12702 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Obesity | 1 | 2018 | 7388 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| Prognosis | 1 | 2017 | 32490 | 0.01 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.01 | Why? |